Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

Figlioli, Gisella ; Brenner, Hermann LU ; Ellberg, Carolina LU orcid ; Hall, Per LU ; Olsson, Håkan LU orcid and Peterlongo, Paolo (2019) In npj Breast Cancer 5(1).
Abstract
Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 are associated with breast cancer risk. FANCM, which encodes for a DNA translocase, has been proposed as a breast cancer predisposition gene, with greater effects for the ER-negative and triple-negative breast cancer (TNBC) subtypes. We tested the three recurrent protein-truncating variants FANCM:p.Arg658*, p.Gln1701*, and p.Arg1931* for association with breast cancer risk in 67,112 cases, 53,766 controls, and 26,662 carriers of pathogenic variants of BRCA1 or BRCA2. These three variants were also studied functionally by measuring survival and chromosome fragility in FANCM−/−... (More)
Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 are associated with breast cancer risk. FANCM, which encodes for a DNA translocase, has been proposed as a breast cancer predisposition gene, with greater effects for the ER-negative and triple-negative breast cancer (TNBC) subtypes. We tested the three recurrent protein-truncating variants FANCM:p.Arg658*, p.Gln1701*, and p.Arg1931* for association with breast cancer risk in 67,112 cases, 53,766 controls, and 26,662 carriers of pathogenic variants of BRCA1 or BRCA2. These three variants were also studied functionally by measuring survival and chromosome fragility in FANCM−/− patient-derived immortalized fibroblasts treated with diepoxybutane or olaparib. We observed that FANCM:p.Arg658* was associated with increased risk of ER-negative disease and TNBC (OR = 2.44, P = 0.034 and OR = 3.79; P = 0.009, respectively). In a country-restricted analysis, we confirmed the associations detected for FANCM:p.Arg658* and found that also FANCM:p.Arg1931* was associated with ER-negative breast cancer risk (OR = 1.96; P = 0.006). The functional results indicated that all three variants were deleterious affecting cell survival and chromosome stability with FANCM:p.Arg658* causing more severe phenotypes. In conclusion, we confirmed that the two rare FANCM deleterious variants p.Arg658* and p.Arg1931* are risk factors for ER-negative and TNBC subtypes. Overall our data suggest that the effect of truncating variants on breast cancer risk may depend on their position in the gene. Cell sensitivity to olaparib exposure, identifies a possible therapeutic option to treat FANCM-associated tumors. © 2019, The Author(s). (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
author collaboration
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
arginine, arginine 658, ATM protein, BRCA1 protein, BRCA2 protein, butadiene diepoxide, checkpoint kinase 2, olaparib, partner and localizer of BRCA2, unclassified drug, Article, ATM protein gene, BRCA1 protein gene, BRCA2 protein gene, cell survival, checkpoint kinase 2 gene, chromosomal instability, chromosome fragility, controlled study, FANCM gene, female, gene, gene expression, gene mutation, genotype, human, informed consent, major clinical study, mRNA expression level, partner and localizer of BRCA2 gene, phenotype, priority journal, risk factor, sensitivity analysis, survival rate, triple negative breast cancer, Western blotting
in
npj Breast Cancer
volume
5
issue
1
article number
38
publisher
Nature Publishing Group
external identifiers
  • pmid:31700994
  • scopus:85074364016
ISSN
2374-4677
DOI
10.1038/s41523-019-0127-5
language
English
LU publication?
yes
id
c1cc6d81-4544-45eb-b7dc-dd5e1a5e72ba
date added to LUP
2020-01-27 14:19:59
date last changed
2024-02-16 09:19:52
@article{c1cc6d81-4544-45eb-b7dc-dd5e1a5e72ba,
  abstract     = {{Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 are associated with breast cancer risk. FANCM, which encodes for a DNA translocase, has been proposed as a breast cancer predisposition gene, with greater effects for the ER-negative and triple-negative breast cancer (TNBC) subtypes. We tested the three recurrent protein-truncating variants FANCM:p.Arg658*, p.Gln1701*, and p.Arg1931* for association with breast cancer risk in 67,112 cases, 53,766 controls, and 26,662 carriers of pathogenic variants of BRCA1 or BRCA2. These three variants were also studied functionally by measuring survival and chromosome fragility in FANCM−/− patient-derived immortalized fibroblasts treated with diepoxybutane or olaparib. We observed that FANCM:p.Arg658* was associated with increased risk of ER-negative disease and TNBC (OR = 2.44, P = 0.034 and OR = 3.79; P = 0.009, respectively). In a country-restricted analysis, we confirmed the associations detected for FANCM:p.Arg658* and found that also FANCM:p.Arg1931* was associated with ER-negative breast cancer risk (OR = 1.96; P = 0.006). The functional results indicated that all three variants were deleterious affecting cell survival and chromosome stability with FANCM:p.Arg658* causing more severe phenotypes. In conclusion, we confirmed that the two rare FANCM deleterious variants p.Arg658* and p.Arg1931* are risk factors for ER-negative and TNBC subtypes. Overall our data suggest that the effect of truncating variants on breast cancer risk may depend on their position in the gene. Cell sensitivity to olaparib exposure, identifies a possible therapeutic option to treat FANCM-associated tumors. © 2019, The Author(s).}},
  author       = {{Figlioli, Gisella and Brenner, Hermann and Ellberg, Carolina and Hall, Per and Olsson, Håkan and Peterlongo, Paolo}},
  issn         = {{2374-4677}},
  keywords     = {{arginine; arginine 658; ATM protein; BRCA1 protein; BRCA2 protein; butadiene diepoxide; checkpoint kinase 2; olaparib; partner and localizer of BRCA2; unclassified drug; Article; ATM protein gene; BRCA1 protein gene; BRCA2 protein gene; cell survival; checkpoint kinase 2 gene; chromosomal instability; chromosome fragility; controlled study; FANCM gene; female; gene; gene expression; gene mutation; genotype; human; informed consent; major clinical study; mRNA expression level; partner and localizer of BRCA2 gene; phenotype; priority journal; risk factor; sensitivity analysis; survival rate; triple negative breast cancer; Western blotting}},
  language     = {{eng}},
  number       = {{1}},
  publisher    = {{Nature Publishing Group}},
  series       = {{npj Breast Cancer}},
  title        = {{The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer}},
  url          = {{http://dx.doi.org/10.1038/s41523-019-0127-5}},
  doi          = {{10.1038/s41523-019-0127-5}},
  volume       = {{5}},
  year         = {{2019}},
}